Question

Pt 33

y.o, male , 135kg , 172cm , dignoed with mv+ av stenosis taking the
following medication:

warfarin
5mg---1*1---oral

acetlylsalicylic
acid---oral---100mg---1*1

enoxeprain
sub q---60mg---1*2

i

Answer 1

The patient has MV and AV stenosis and is on a regimen to prevent clot formation. Pharmacogenomics can personalize warfarin dosing to enhance treatment safety by accounting for genetic variations that affect drug metabolism. Proper dosing reduces the risks of overdose or underdose in patients.

Step-by-step explanation:

The patient being discussed is a male weighing 135kg with a height of 172cm, diagnosed with mitral valve (MV) and aortic valve (AV) stenosis, and is on a regimen including warfarin 5mg once daily, oral acetylsalicylic acid 100mg once daily, and enoxaparin 60mg subcutaneously twice daily. Warfarin is an anticoagulant drug used to prevent blood clots, acetylsalicylic acid (aspirin) is also used to prevent clotting issues, and enoxaparin is a low molecular weight heparin used for similar purposes. These medications reduce the risk of stroke or heart attack in patients with valve problems like stenosis by preventing excessive blood clot formation.

Pharmacogenomics can help with personalizing warfarin dosing for patients. Since warfarin dosing can be complex and is influenced by genetic factors affecting liver function and vitamin K metabolism, pharmacogenomics tests can identify patients' specific genetic variations. This can lead to more accurate warfarin dosing, reducing the risk of overdose or underdose, and thus can enhance treatment safety and efficacy.